Apr 07, 2021 7:05am EDT IMV Announces Company-Sponsored Clinical Trial in Patients with r/rDLBCL in Collaboration with Merck Following Feedback from FDA
Mar 17, 2021 7:05am EDT IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results
Mar 08, 2021 7:05am EST IMV to Announce Fourth Quarter and Fiscal 2020 Financial and Operational Results and Host Conference Call and Webcast on March 17, 2021
Mar 01, 2021 7:05am EST IMV to Participate at the upcoming H.C. Wainwright Global Life Sciences Conference
Dec 06, 2020 8:15am EST Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting
Dec 03, 2020 7:10am EST IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer
Nov 13, 2020 7:05am EST IMV to Host a Key Opinion Leader Webcast on the Ovarian Cancer Treatment Landscape and Data Highlights from the Phase 2 Trial of a Novel T-Cell Therapy
